These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 26274799)

  • 21. Prevention of ischaemic stroke--antiplatelets.
    McCabe DJ; Brown MM
    Br Med Bull; 2000; 56(2):510-25. PubMed ID: 11092100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aggrenox: a combination of antiplatelet drugs for stroke prevention.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):11-2. PubMed ID: 10725967
    [No Abstract]   [Full Text] [Related]  

  • 23. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
    Jamieson DG; Parekh A; Ezekowitz MD
    J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspirin and antiplatelet agent resistance: implications for prevention of secondary stroke.
    Greer DM
    CNS Drugs; 2010 Dec; 24(12):1027-40. PubMed ID: 20932071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
    Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
    J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on the use of antiplatelet agents in secondary stroke prevention.
    Jamieson DG
    J Natl Med Assoc; 2007 Mar; 99(3):306. PubMed ID: 17393957
    [No Abstract]   [Full Text] [Related]  

  • 27. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
    Warlow C
    Stroke; 2002 Aug; 33(8):2137-8. PubMed ID: 12154276
    [No Abstract]   [Full Text] [Related]  

  • 28. Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence-based review.
    Simmons BB; Yeo A; Fung K; ;
    Postgrad Med; 2010 Mar; 122(2):49-53. PubMed ID: 20203455
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAPRIE trial.
    Barer D
    Lancet; 1997 Feb; 349(9048):355-6. PubMed ID: 9024397
    [No Abstract]   [Full Text] [Related]  

  • 30. Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
    Eriksson P
    Am J Med; 2005 Feb; 118(2):199-200; author reply 200. PubMed ID: 15694910
    [No Abstract]   [Full Text] [Related]  

  • 31. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease.
    Spinler SA
    Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on clinical trials of antiplatelet therapy for cerebrovascular diseases.
    Bhatt DL; Kapadia SR; Yadav JS; Topol EJ
    Cerebrovasc Dis; 2000; 10 Suppl 5():34-40. PubMed ID: 11096181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiplatelet treatment in primary and secondary stroke prevention in women.
    Caso V; Santalucia P; Acciarresi M; Pezzella FR; Paciaroni M
    Eur J Intern Med; 2012 Oct; 23(7):580-5. PubMed ID: 22939800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiplatelets and stroke outcomes: state of the science.
    Meyer D
    Crit Care Nurs Clin North Am; 2009 Dec; 21(4):517-28. PubMed ID: 19951767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antiplatelet therapy for secondary prevention of acute coronary syndrome, transient ischemic attack, and noncardioembolic stroke in an era of cost containment.
    Kessler C; Thomas K; Kao J
    J Investig Med; 2012 Jun; 60(5):792-800. PubMed ID: 22460233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 39. [Calculation of costs of stroke, cost effectiveness of stroke units and secondary prevention in patients after a stroke, as recommended by revised CBO practice guideline 'Stroke'].
    Niessen LW; Dippel DW; Limburg M
    Ned Tijdschr Geneeskd; 2000 Oct; 144(41):1959-64. PubMed ID: 11048560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New insights in antiplatelet therapy for patients with ischemic stroke.
    Chaturvedi S; Bhattacharya P
    Neurologist; 2011 Sep; 17(5):255-62. PubMed ID: 21881467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.